黄馨祥，世界上最富裕的医生（价值?$ 200亿）宣布：
Cancer Moonshot 2020: Patrick Soon-Shiong, the richest physician on earth (worth ~$20 billion) announced:
calls itself Cancer Moonshot 2020 and also includes academic institutions and insurers. Its leaders hope to get competing drug and biotech companies to work together on the combination treatments rather than developing their own compounds in isolation.
?
听起来你wantta“跳舞与癌症” - 你怎么编排的舞蹈？怎么样？一个亿万富翁企业家已经拉到一起制药公司组成的联盟，以加速什么的研究人员认为，可能是对抗癌症的有力武器发展 - 新的药物，利用人体的免疫系统，有效的组合。
所谓免疫疗法有助于抵抗疾病的细胞攻击肿瘤。然而，研究人员认为，他们可能工作最好当两个，三个或多种药物一起使用 - 铺天盖地肿瘤的细胞防御来自各方面的攻击。
帕特里克汇聚了一群淳菘自称登月2020年也包括学术机构和保险公司。它的领导人希望得到竞争性药物和生物技术公司的联合治疗一起工作，而不是发展自己的化合物隔离。
“这里的主要贡献是运行的组合研究，药品从多个制药公司在快速运转的能力，”曼努埃尔·伊达尔戈，癌症中心的贝斯以色列女执事医疗中心在波士顿临床主任说。 “有未经批准的药物从不同的制药公司联合研究是不容易做到的，我们希望能够结合三，四药，而不是两个。”
虽然免疫疗法有自己的副作用，医生都希望他们可以更好地适应患者的肿瘤的空间，有朝一日取代或补充化疗，这被认为是为具有高毒性钝工具。
该集团的目标是完成的临床试验达20肿瘤类型中为多达2万??例，到2020年，根据在旧金山举行的摩根大通保健大会发表了一份声明。参与制药公司安进公司包括公司，Celgene的公司，葛兰素史克公司和NantWorks有限责任公司，以及医疗保险公司独立蓝十字和美国公司，这是自保险的银行，根据该声明。
拜登会议
该联盟的成员会见了美国副总统约瑟夫·拜登，谁在一个“登月”，需要治愈癌症十一月份发表讲话说，与淳菘会谈后，拜登的讲话来了，这位亿万富翁说，该联盟还没有问奥巴马政府的财政支持，根据NantWorks。
所有的20000例患者都会有他们的肿瘤基因测序，该计划是建立一个病人登记，其中制药公司可以寻找适合的标准，他们的审判具体的患者，称淳菘，NantWorks首席执行官。淳菘成为通过药物公司，他开始了一个亿万富翁，销售，APP制药公司和Abraxis公司BioScience公司
“在大型制药公司现在人们意识到，他们不能孤军奋战，”淳菘在接受采访时说，该联盟是在非常早期的阶段，尚未确定还多少每个参与者可能提供财政捐助和集团如何将集体保持患者的数据库，他说。
独立蓝十字会涉及与试验为它的成员门诊费用，也将涵盖淳菘的公司NantHealth进行基因测序，根据女发言人伊丽莎白出售。费城为基础的健康保险覆盖1000万人在34个州和华盛顿特区，根据其网站。
A billionaire entrepreneur has pulled together a coalition of drugmakers to speed development of what researchers believe could be a powerful weapon against cancers -- potent combinations of new drugs that harness the body’s immune system.
So-called immunotherapies help disease-fighting cells attack tumors. Yet researchers believe they may work best when two, three or more of the drugs are used together -- overwhelming a tumor’s cellular defenses with attacks from all sides.
The group brought together by Patrick Soon-Shiong calls itself Moonshot 2020 and also includes academic institutions and insurers. Its leaders hope to get competing drug and biotech companies to work together on the combination treatments rather than developing their own compounds in isolation.
“The key contribution here is the ability to run combination studies with drugs from multiple pharma companies in a rapid manner,” said Manuel Hidalgo, clinical director of the Cancer Center at Beth Israel Deaconess Medical Center in Boston. “Combination studies with unapproved drugs from different pharma companies are not easy to do, and we want to be able combine three to four drugs, not just two."
While the immunotherapies have side effects of their own, physicians have hoped they can be better tailored to a patient’s tumor profile, and someday replace or supplement chemotherapy, which is thought of as a blunt tool with high toxicity.
The group aims to complete clinical trials for up to 20 tumor types in as many as 20,000 patients by the year 2020, according to a statement issued at the J.P. Morgan Healthcare Conference in San Francisco. Participating drugmakers include Amgen Inc., Celgene Corp., GlaxoSmithKline Plc and NantWorks LLC, as well as health insurer Independence Blue Cross and Bank of America Corp., which is self-insured, according to the statement.
Biden Meeting
Members of the coalition met with U.S. Vice President Joseph Biden, who said in a November speech that a “moonshot" was needed to cure cancer. Biden’s speech came after meeting with Soon-Shiong, the billionaire said. The coalition hasn’t asked the Obama administration for financial support, according to NantWorks.
All 20,000 patients will have their tumors genetically sequenced, and the plan is to create a patient registry where drugmakers can search for specific patients that fit the criteria for their trials, said Soon-Shiong, chief executive officer of NantWorks. Soon-Shiong became a billionaire through drug companies he started and sold, APP Pharmaceuticals Inc. and Abraxis BioScience Inc.
“People in large pharma now realize they can’t go it alone," Soon-Shiong said in an interview. The coalition is in very early stages and hadn’t determined yet how much each participant might contribute financially and how the group would collectively maintain a database of patients, he said.
Independence Blue Cross will cover patient costs related to trials for its members, and will also cover genomic sequencing performed by Soon-Shiong’s company NantHealth, according to spokeswoman Elizabeth Sell. The Philadelphia-based health insurer covers 10 million people in 34 states and Washington, D.C., according to its website.
与癌共舞 （1）- 是时候了，停止人们死于癌症！澳大利亚 周家馨
| 推荐到群组
与癌共舞 （1）
- 是时候了，停止人们死于癌症！
澳大利亚 周家馨
今晨打开邮箱，看见从 the NCCN （the National Comprehensive Cancer Network，美国全方位癌症联合会）发给我的一封邮件。因为我从 2013 年以来，一直是这个联合会的会员。
美国奥巴马总统和拜登副总统联手，向全球的我们，吹起了向癌症宣战的极强冲锋号。
The NCCN 的 CEO Robert W. Carlson 宣告，“It is time that people stop dying of cancer."
是时候了，停止人们死于癌症！
邮件中还附了拜登副总统，亲自给我们大家，写的一封声情并茂，感人肺腑的公开信。他46岁的大儿子波·拜登因脑癌，上周六逝世。
他说：
“ It’s personal for me. But it’s also personal for nearly every American, and millions of people around the world. We all know someone who has had cancer, or is fighting to beat it. They’re our family, friends, and co-workers.
这是对我有私人感触的一件事，也是几乎对每一个美国人有私人感触的事，和对全世界千百万人有私人感触的事。我们全都知道，认识，一个患过癌症的人，或者正在与癌症抗争，想要战胜癌症的人。 他们是我们的家庭，朋友，和共事的人。”
.......
我就可以证实，这也是对我，有很深的私人感触的一件事。我会在有机会的时候，与大家分享共勉。
让癌症细胞，在下了决心要战胜它的主人面前，发抖吧。
周家馨
2016-01-14
写于布里斯本家中
http://blog.sciencenet.cn/blog-2981069-950365.html 此文来自科学网周家馨博客，转载请注明出处。
上一篇：七十抒怀，答谢网友 澳大利亚 周家馨 2016-01-09
1 李胜文
发表评论 评论 (2 个评论)
- [2]李胜文
- "癌症的起因搞清了吗？这就让癌细胞发抖？" Sounds you wantta "dance with cancer" - How do you choreograph your dancer? HOW?
- [1]印大中
- 癌症的起因搞清了吗？这就让癌细胞发抖？
- ~~~~~~~~~~~~~~~~~~~~~~~
- A Billionaire's Cancer Moonshot
Patrick Soon-Shiong.
Photographer: Danny Moloshok/AP-
Amgen, Celgene, GSK, Independence Blue Cross join coalition
-
`Moonshot' group aims for trials in 20,000 patients by 2020
A billionaire entrepreneur has pulled together a coalition of drugmakers to speed development of what researchers believe could be a powerful weapon against cancers -- potent combinations of new drugs that harness the body’s immune system.
So-called immunotherapies help disease-fighting cells attack tumors. Yet researchers believe they may work best when two, three or more of the drugs are used together -- overwhelming a tumor’s cellular defenses with attacks from all sides.
The group brought together by Patrick Soon-Shiong calls itself Moonshot 2020 and also includes academic institutions and insurers. Its leaders hope to get competing drug and biotech companies to work together on the combination treatments rather than developing their own compounds in isolation.
“The key contribution here is the ability to run combination studies with drugs from multiple pharma companies in a rapid manner,” said Manuel Hidalgo, clinical director of the Cancer Center at Beth Israel Deaconess Medical Center in Boston. “Combination studies with unapproved drugs from different pharma companies are not easy to do, and we want to be able combine three to four drugs, not just two."
While the immunotherapies have side effects of their own, physicians have hoped they can be better tailored to a patient’s tumor profile, and someday replace or supplement chemotherapy, which is thought of as a blunt tool with high toxicity.
The group aims to complete clinical trials for up to 20 tumor types in as many as 20,000 patients by the year 2020, according to a statement issued at the J.P. Morgan Healthcare Conference in San Francisco. Participating drugmakers include Amgen Inc., Celgene Corp., GlaxoSmithKline Plc and NantWorks LLC, as well as health insurer Independence Blue Cross and Bank of America Corp., which is self-insured, according to the statement.
Biden Meeting
Members of the coalition met with U.S. Vice President Joseph Biden, who said in a November speech that a “moonshot" was needed to cure cancer. Biden’s speech came after meeting with Soon-Shiong, the billionaire said. The coalition hasn’t asked the Obama administration for financial support, according to NantWorks.
All 20,000 patients will have their tumors genetically sequenced, and the plan is to create a patient registry where drugmakers can search for specific patients that fit the criteria for their trials, said Soon-Shiong, chief executive officer of NantWorks. Soon-Shiong became a billionaire through drug companies he started and sold, APP Pharmaceuticals Inc. and Abraxis BioScience Inc.
“People in large pharma now realize they can’t go it alone," Soon-Shiong said in an interview. The coalition is in very early stages and hadn’t determined yet how much each participant might contribute financially and how the group would collectively maintain a database of patients, he said.
Independence Blue Cross will cover patient costs related to trials for its members, and will also cover genomic sequencing performed by Soon-Shiong’s company NantHealth, according to spokeswoman Elizabeth Sell. The Philadelphia-based health insurer covers 10 million people in 34 states and Washington, D.C., according to its website.
-
